Keytruda

Phase 2

Innovent Biologics Inc/ADR (IVBXF)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

IVBXFPhase 2$24.9B

Keytruda Phase 2 Est. Readout

Keytruda• Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer170

Nov 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

View Full Landscape

Drug Information

Target Indication

Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Clinical Trial

NCT07122687

Last updated: 10/3/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IVBXF

Innovent Biologics Inc/ADR

Biotechnology•North America•NASDAQ

Related Pipeline

Aflibercept OphthalmicPhase 3

Neovascular Age-related Macular Degeneration

FebuxostatPhase 3

Gout

Investigator's choice of therapyPhase 3

Colorectal Cancer

PicankibartPhase 3

Plaque Psoriasis

IBI301 plus CHOPPhase 3

Diffuse, Large B-Cell, Lymphoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts